Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page
- ChecktodayChange DetectedThe page's revision tag was updated to v3.5.5, replacing v3.5.4. This represents a small internal update to the page's revision history and does not change the displayed study information.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now displays a new revision label (v3.5.4), replacing the previous v3.5.3. This update reflects a new page revision in the metadata and does not change the underlying study content.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3. This reflects a tooling/version update without indicating changes to the study details.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded 'B-cell chronic lymphocytic leukemia' as a disease keyword on the Study Details page.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision tag updated to v3.5.0, replacing the previous v3.4.3. No visible changes to study details or page layout.SummaryDifference0.1%

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.